BioXcel Therapeutics, Inc. To Discuss Achieved Targeted Exposures of BXCL501 Conference Call Transcript
Good morning, and welcome to the BioXcel Therapeutics Phase I pharmacokinetic bioavailability and safety study results of BXCL501 conference call and webcast. (Operator Instructions)
I will now turn the conference over to Carol Ruth. Please go ahead, ma'am.
Okay. Thank you, operator. Just to remind everyone, certain matters discussed in today's conference call or answers that may be given to questions as -- are forward-looking statements that are subject to risk and uncertainties relating to future events, including, but not limited to, the advancement and development of BXCL501. Actual results could differ materially than those anticipated in these forward-looking statements.
The risk factors and other uncertainties that may affect results are detailed in our most recent public filings with the SEC, including our quarterly report on Form 10-Q for the quarter period ended March 31, 2019, which can be found on our website,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |